
🌟 We’re counting down the days and getting excited for the adventure ahead 🌟…
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.

> 50 countries approved registrations
> 175 shared cases on LinkedIn; > 400 reported cases
> 35 distributor agreements
> 45 hospitals use iVAC 2L on a regular base; > 9 Centers of Excellence.
> 600 patients world wide treated by iVAC 2L
> 30 publications
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
20-11-2025
11-11-2025
01-09-2025
31-07-2025
Clinical programme supported by leading cardiologists